Lab study reveals how HIV drug crosses the placenta
NCT ID NCT02020083
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study used donated placentas from 369 pregnant women to understand how the HIV drug tenofovir moves from mother to baby. Researchers used a special lab model that mimics the third trimester of pregnancy. The goal was to see if certain proteins or drug interactions affect how much tenofovir reaches the fetus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tenofovir
- What this could lead to
- If successful, this could help doctors understand how tenofovir moves through the placenta, potentially leading to safer use of this drug during pregnancy.
- What could go wrong
- This is a lab study using donated placentas, not a treatment trial. Results may not fully reflect what happens in the body, and the study does not test any new drug or therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maternité de Port Royal
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new care protocol aims to support pregnant women in disaster zones
- Could a hidden back tissue hold the key to pelvic pain in pregnancy?
- Pregnancy's hidden strain: measuring the Back's inner support tissue
- Home kit boosts emotional bond between parents and unborn baby
- Which folate supplement works best for Moms-to-Be?
- Epidural analgesia in labor: could it shape your Baby's future?